Offstream
news

---

Changes

1. United Arab Emirates announces to roll out the Sinopharm vaccine doses to all adult population of nine million UAE citizens.
   2020-12-23 01:05:07 (First version)
2. The United Arab Emirates announces that they will roll out the Sinopharm vaccine to all adult UAE citizens.
   (Current version)

---

Related

The South African Health Products Regulatory Authority approves the use of the Sinopharm BBIBP COVID-19 vaccine for adults aged above 18 years.
2022-02-7

The Ministry of Health approves the emergency use of the Sinopharm BBIBP-CorV vaccine for children between the ages of 3 and 17 years old in the UAE.
2021-08-2

Solomon Islands receives 50,000 doses of the Sinopharm BBIBP-CorV vaccine from China.
2021-04-12

Iran receives their first shipment of 250,000 doses of the Sinopharm BBIBP-CorV vaccine.
2021-02-28

Nepal approves the emergency use of the Sinopharm vaccine, which is the second vaccine to be approved in the country.
2021-02-18

Pakistan approves the emergency use of China's CanSinoBio vaccine, becoming the fourth vaccine to be approved in the country.
2021-02-12

Pakistan approves the emergency use of Russia's Sputnik V vaccine, becoming the third vaccine to be approved in the country after the Sinopharm and Oxford-AstraZeneca vaccines.
2021-02-9

Egypt receives its first shipment of 50,000 of Sinopharm's vaccine, making it the first African country to receive COVID-19 vaccines. The shipment was provided as a gift from the United Arab Emirates, which recently announced that the vaccine had an 86% efficacy based on Phase III testing results.
2020-12-11

Indonesia aims to start administering COVID-19 vaccines early next month, according to the Coordinating Ministry for Maritime and Investment Affairs. Sinopharm and G42 Healthcare will supply five million doses starting next month, CanSino Biologics will supply 100,000 doses that same time, and Sinovac will supply three million doses of CoronaVac by December. All three vaccines are currently in Phase III trials in various countries.
2020-10-12

Sinopharm began Phase III trials in Peru starting with two dozen people, with the goal to vaccinate 6,000 people between the ages of 18 and 75. So far, Sinopharm has given 30,000 doses to volunteers and another 10,000 participants have received double doses in Bahrain and the United Arab Emirates, with additional trials planned for Morocco and Argentina.
2020-09-10